LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML)

Summary

The purpose of this study is to evaluate the effectiveness of post-induction lenalidomide in patients with de novo AML with deletion 5q cytogenetic abnormality (del (5q)) or monosomy 5 (-5), who obtained complete remission after conventional induction chemotherapy. So, too, for those who no obtained response treatment (total resistance) or partial remission. At the same time, the study evaluate the security of lenalidomide.

Timeline

Start

2011-01

Primary completion

2013-02

Completion

2013-02

Drugs

Indications